Prevalence of benign disease diagnosis after lung surgery varied widely by state

Benign disease diagnosis rates after surgery for suspected lung cancer varied widely by state, and the reasons for these variations could inform health policy and clinical guidelines for lung cancer screening, according to a researcher who presented the data at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10.

"Given the results of the National Lung Screening Trial (NLST), which demonstrated that low-dose computed tomography (CT) reduces mortality, and the support for screening healthy, high-risk individuals with low-dose CT by clinical and patient advocacy groups, we will likely see screening for lung cancer in our near future," said Stephen A. Deppen, a doctoral candidate in epidemiology and database analyst at Vanderbilt University in Nashville, Tenn.

Data from NLST revealed that low-dose led to a 20 percent reduction in lung cancer-related mortality compared with ; however, 96 percent of the positive screening results were false positives and 24 percent of follow-up lung resections were negative for lung cancer.

"It was not known whether the prevalence of benign after lung resection for suspected lung cancer is uniform across the United States," said Deppen. "If prevalence differs by state or region of the country, then a national program may have varying results."

He and his colleagues, therefore, set out to determine the prevalence of benign disease diagnosis rates by state.

Using the Medicare Provider Analysis and Review (MedPAR) Hospital National Limited Data Set from 2009, Deppen and colleagues evaluated medical data from 25,362 patients who underwent lung surgery for known or suspected lung cancer.

They found that 2,312 patients (9.1 percent) had a benign disease diagnosis after surgery. About 2.3 percent of all patients died in the hospital after the procedure. For those who were found not to have lung cancer, the mortality rate was 2.1 percent.

In addition, there was a wide variation among states in the prevalence of benign disease diagnosis, from 1.2 percent in Vermont to 25 percent in Hawaii.

"States with a higher rate of false positives and higher benign disease prevalence may observe poorer performance of a screening program for lung cancer," Deppen said. "The benefit of for lung cancer is finding early-stage disease and reducing mortality from lung cancer. Lung surgery is major surgery and has a much higher risk for death and complications compared with diagnostic operations for other cancers, such as breast and prostate cancer. So, more surgeries for benign disease will result in more deaths and harm from the diagnostic process and will reduce the benefit that was observed in the original NLST."

Related Stories

Model more accurately predicts lung cancer risk

date Feb 22, 2013

(HealthDay)—A new model to predict lung cancer risk is more accurate than previous criteria, according to a study published in the Feb. 21 issue of the New England Journal of Medicine.

Recommended for you

Spicy treatment the answer to aggressive cancer?

date Jul 03, 2015

It has been treasured by food lovers for thousands of years for its rich golden colour, peppery flavour and mustardy aroma…and now turmeric may also have a role in fighting cancer.

Cancer survivors who smoke perceive less risk from tobacco

date Jul 02, 2015

Cancer survivors who smoke report fewer negative opinions about smoking, have more barriers to quitting, and are around other smokers more often than survivors who had quit before or after their diagnosis, according to a ...

Melanoma mutation rewires cell metabolism

date Jul 02, 2015

A mutation found in most melanomas rewires cancer cells' metabolism, making them dependent on a ketogenesis enzyme, researchers at Winship Cancer Institute of Emory University have discovered.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.